Houses of the Oireachtas

All parliamentary debates are now being published on our new website. The publication of debates on this website will cease in December 2018.

Go to

Health (Pricing and Supply of Medical Goods) Bill 2012 [Seanad]: Report Stage (Resumed) (Continued)

Wednesday, 24 April 2013

Dáil Éireann Debate
Vol. 800 No. 4

First Page Previous Page Page of 92 Next Page Last Page

Deputy Billy Kelleher: Information on Billy Kelleher Zoom on Billy Kelleher I move amendment No. 3:

In page 13, between lines 17 and 18, to insert the following:

"(3) The Board shall arrange for that part of its Internet website which contains the List of non-Interchangeable Medicinal Products to ordinarily be accessible by members of the public.".

  Amendment put and declared lost.

Acting Chairman (Deputy Ann Phelan): Information on Ann Phelan Zoom on Ann Phelan Amendments Nos. 4 and 18 are related and may be discussed together.

Deputy Caoimhghín Ó Caoláin: Information on Caoimhghín Ó Caoláin Zoom on Caoimhghín Ó Caoláin I move amendment No. 4:

In page 14, between lines 23 and 24, to insert the following:

"(3) The Board shall, in determining an application under subsection (2), have regard to the desirability with respect to efficacy and safety of refusing to add medicinal product in the anti-epileptic drug class, used in the treatment of persons with epilepsy for the purpose of preventing seizures, to the List of Interchangeable Medicinal Products.".

I am joined in presenting that amendment by Deputies Catherine Murphy and Billy Kelleher. As I indicated in the earlier engagement in respect of amendments Nos. 1 to 3, inclusive, this is the meat of what we are about in the Health (Pricing and Supply of Medical Goods) Bill 2012. Amendments Nos. 4 and 18 get to the nub of the issue. These amendments arise from the concerns of people with epilepsy. Concerns about the need to ensure that there is no inappropriate substitution of their medication is not a small matter: it is a hugely important issue. As he has indicated, the Minister is well aware of the concerns of people with epilepsy in this regard and has confirmed that today. There is a particular issue with regard to the precise formulation of anti-epileptic drugs, AEDs, and the concern that generic substitutions are not exact replicas and with possibly very negative consequences.

Last Updated: 29/04/2020 08:42:19 First Page Previous Page Page of 92 Next Page Last Page